JP2021504423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504423A5 JP2021504423A5 JP2020529550A JP2020529550A JP2021504423A5 JP 2021504423 A5 JP2021504423 A5 JP 2021504423A5 JP 2020529550 A JP2020529550 A JP 2020529550A JP 2020529550 A JP2020529550 A JP 2020529550A JP 2021504423 A5 JP2021504423 A5 JP 2021504423A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- intended
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 33
- 230000002265 prevention Effects 0.000 claims 13
- 206010012601 diabetes mellitus Diseases 0.000 claims 11
- 229960001713 canagliflozin Drugs 0.000 claims 10
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 10
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 229960003834 dapagliflozin Drugs 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 229960003345 empagliflozin Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 3
- 230000007211 cardiovascular event Effects 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- HYTPDMFFHVZBOR-VNXMGFANSA-N (1r,2s,3s,4r,5r)-5-[4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=C(F)C(OCC)=CC=C1CC1=CC([C@]23O[C@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl HYTPDMFFHVZBOR-VNXMGFANSA-N 0.000 claims 2
- BUXGTLNOWLNUKF-SOVHRIKKSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]thiophen-3-yl]oxyoxane-3,4,5-triol Chemical compound C1=CC(OC)=CC=C1CC1=C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=CS1 BUXGTLNOWLNUKF-SOVHRIKKSA-N 0.000 claims 2
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000008960 Diabetic foot Diseases 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims 2
- 229950002400 atigliflozin Drugs 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 238000010586 diagram Methods 0.000 claims 2
- -1 ertzgliflozin Chemical compound 0.000 claims 2
- 229950000991 ipragliflozin Drugs 0.000 claims 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims 2
- 238000011542 limb amputation Methods 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- 229950004397 luseogliflozin Drugs 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 229940126844 remogliflozin Drugs 0.000 claims 2
- 229950005268 sotagliflozin Drugs 0.000 claims 2
- 229950006667 tofogliflozin Drugs 0.000 claims 2
- BTCRKOKVYTVOLU-SJSRKZJXSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(OCCOC3CC3)=CC=2)=C1 BTCRKOKVYTVOLU-SJSRKZJXSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 229950003611 bexagliflozin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023209979A JP7635355B2 (ja) | 2017-11-30 | 2023-12-13 | ４－ピリミジンスルファミド誘導体のｓｇｌｔ－２阻害剤との、エンドセリン関連疾患治療用の合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017081050 | 2017-11-30 | ||
| EPPCT/EP2017/081050 | 2017-11-30 | ||
| PCT/EP2018/082947 WO2019106066A1 (en) | 2017-11-30 | 2018-11-29 | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209979A Division JP7635355B2 (ja) | 2017-11-30 | 2023-12-13 | ４－ピリミジンスルファミド誘導体のｓｇｌｔ－２阻害剤との、エンドセリン関連疾患治療用の合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504423A JP2021504423A (ja) | 2021-02-15 |
| JP2021504423A5 true JP2021504423A5 (https=) | 2022-01-06 |
| JP7404235B2 JP7404235B2 (ja) | 2023-12-25 |
Family
ID=64606962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529550A Active JP7404235B2 (ja) | 2017-11-30 | 2018-11-29 | ４－ピリミジンスルファミド誘導体のｓｇｌｔ－２阻害剤との、エンドセリン関連疾患治療用の合剤 |
| JP2023209979A Active JP7635355B2 (ja) | 2017-11-30 | 2023-12-13 | ４－ピリミジンスルファミド誘導体のｓｇｌｔ－２阻害剤との、エンドセリン関連疾患治療用の合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209979A Active JP7635355B2 (ja) | 2017-11-30 | 2023-12-13 | ４－ピリミジンスルファミド誘導体のｓｇｌｔ－２阻害剤との、エンドセリン関連疾患治療用の合剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12144811B2 (https=) |
| EP (1) | EP3716979B1 (https=) |
| JP (2) | JP7404235B2 (https=) |
| KR (2) | KR20200094187A (https=) |
| CN (1) | CN111405899B (https=) |
| AU (1) | AU2018376263B2 (https=) |
| BR (1) | BR112020010831A2 (https=) |
| CA (1) | CA3083327A1 (https=) |
| CL (1) | CL2020001394A1 (https=) |
| DK (1) | DK3716979T3 (https=) |
| EA (1) | EA202091324A1 (https=) |
| ES (1) | ES3035734T3 (https=) |
| FI (1) | FI3716979T3 (https=) |
| HR (1) | HRP20250732T1 (https=) |
| HU (1) | HUE071739T2 (https=) |
| IL (1) | IL274943B2 (https=) |
| LT (1) | LT3716979T (https=) |
| MA (1) | MA51203A (https=) |
| MX (1) | MX2020005543A (https=) |
| MY (1) | MY210547A (https=) |
| PH (1) | PH12020550745A1 (https=) |
| PL (1) | PL3716979T3 (https=) |
| PT (1) | PT3716979T (https=) |
| RS (1) | RS66980B1 (https=) |
| SG (1) | SG11202004862XA (https=) |
| SI (1) | SI3716979T1 (https=) |
| TW (1) | TWI809009B (https=) |
| UA (1) | UA127083C2 (https=) |
| WO (1) | WO2019106066A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3658140T3 (fi) | 2017-02-27 | 2025-08-12 | Idorsia Pharmaceuticals Ltd | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi |
| US11723929B2 (en) | 2017-06-13 | 2023-08-15 | The Regents Of The University Of California | Methods of improving cell-based therapy |
| CA3156136A1 (en) * | 2019-11-07 | 2021-05-14 | Michael Hadd | Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals |
| AU2020378025A1 (en) * | 2019-11-07 | 2022-06-23 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of Aprocitentan, preparation method therefor and use thereof |
| KR20220104802A (ko) * | 2019-11-26 | 2022-07-26 | 액테리온 파마슈티칼 리미티드 | 폰탄-완화 환자의 폐 혈관 질환 및/또는 심장 기능장애의 치료를 위한 약제학적 조성물 |
| CA3161516A1 (en) | 2019-12-17 | 2021-06-24 | Philip Thomas FROHLICH | Methods of treating iga nephropathy with atrasentan |
| WO2022009163A1 (en) | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| CN116392472B (zh) * | 2020-07-27 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用达格列净治疗慢性肾脏病的方法 |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| AU2022340358A1 (en) * | 2021-09-02 | 2024-01-04 | Daewoong Therapeutics Inc. | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| JP2025519101A (ja) | 2022-05-22 | 2025-06-24 | イドルシア・ファーマシューティカルズ・リミテッド | 高血圧の治療のための４－ピリミジンスルファミド誘導体の使用 |
| WO2023227721A1 (en) | 2022-05-25 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| EP4615974A1 (en) * | 2022-11-10 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
| CN120390636A (zh) * | 2022-12-20 | 2025-07-29 | 斯法姆公司 | 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的口服药物制剂 |
| WO2025089933A1 (ko) * | 2023-10-24 | 2025-05-01 | 주식회사 레드엔비아 | Sglt-2 저해제 및 dpp-4 저해제를 포함하는 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제 |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| AU2002227984B8 (en) | 2000-12-18 | 2007-01-04 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| ATE431830T1 (de) | 2000-12-28 | 2009-06-15 | Kissei Pharmaceutical | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
| JP4147111B2 (ja) * | 2001-02-27 | 2008-09-10 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体およびその医薬用途 |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
| PL381247A1 (pl) | 2004-03-04 | 2007-05-14 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze |
| CN103030617A (zh) | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CA2655144A1 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| PE20080991A1 (es) | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP4678242A3 (en) * | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| AU2015210898A1 (en) | 2014-01-31 | 2016-07-28 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| US10174010B2 (en) * | 2014-03-19 | 2019-01-08 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof |
| JP2017515797A (ja) * | 2014-04-04 | 2017-06-15 | サノフイ | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物 |
| US20170135981A1 (en) | 2014-05-16 | 2017-05-18 | Astrazeneca Ab | Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor |
| AU2015342929A1 (en) | 2014-11-07 | 2017-05-25 | Abbvie Inc. | Methods of treating CKD using predictors of fluid retention |
| WO2017064679A1 (en) | 2015-10-15 | 2017-04-20 | Lupin Limited | Process for the preparation of amorphous canagliflozin |
| FI3658140T3 (fi) * | 2017-02-27 | 2025-08-12 | Idorsia Pharmaceuticals Ltd | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi |
-
2018
- 2018-11-29 CN CN201880076562.0A patent/CN111405899B/zh active Active
- 2018-11-29 EP EP18814821.7A patent/EP3716979B1/en active Active
- 2018-11-29 LT LTEPPCT/EP2018/082947T patent/LT3716979T/lt unknown
- 2018-11-29 TW TW107142595A patent/TWI809009B/zh active
- 2018-11-29 HU HUE18814821A patent/HUE071739T2/hu unknown
- 2018-11-29 SI SI201831245T patent/SI3716979T1/sl unknown
- 2018-11-29 MX MX2020005543A patent/MX2020005543A/es unknown
- 2018-11-29 KR KR1020207018658A patent/KR20200094187A/ko not_active Ceased
- 2018-11-29 HR HRP20250732TT patent/HRP20250732T1/hr unknown
- 2018-11-29 JP JP2020529550A patent/JP7404235B2/ja active Active
- 2018-11-29 SG SG11202004862XA patent/SG11202004862XA/en unknown
- 2018-11-29 ES ES18814821T patent/ES3035734T3/es active Active
- 2018-11-29 CA CA3083327A patent/CA3083327A1/en active Pending
- 2018-11-29 IL IL274943A patent/IL274943B2/en unknown
- 2018-11-29 DK DK18814821.7T patent/DK3716979T3/da active
- 2018-11-29 WO PCT/EP2018/082947 patent/WO2019106066A1/en not_active Ceased
- 2018-11-29 MA MA051203A patent/MA51203A/fr unknown
- 2018-11-29 PL PL18814821.7T patent/PL3716979T3/pl unknown
- 2018-11-29 FI FIEP18814821.7T patent/FI3716979T3/fi active
- 2018-11-29 MY MYPI2020002671A patent/MY210547A/en unknown
- 2018-11-29 RS RS20250663A patent/RS66980B1/sr unknown
- 2018-11-29 UA UAA202003789A patent/UA127083C2/uk unknown
- 2018-11-29 KR KR1020267004128A patent/KR20260037123A/ko active Pending
- 2018-11-29 US US16/768,604 patent/US12144811B2/en active Active
- 2018-11-29 PT PT188148217T patent/PT3716979T/pt unknown
- 2018-11-29 AU AU2018376263A patent/AU2018376263B2/en active Active
- 2018-11-29 BR BR112020010831-6A patent/BR112020010831A2/pt not_active Application Discontinuation
- 2018-11-29 EA EA202091324A patent/EA202091324A1/ru unknown
-
2020
- 2020-05-27 CL CL2020001394A patent/CL2020001394A1/es unknown
- 2020-05-29 PH PH12020550745A patent/PH12020550745A1/en unknown
-
2023
- 2023-12-13 JP JP2023209979A patent/JP7635355B2/ja active Active
-
2024
- 2024-10-28 US US18/929,609 patent/US20250120973A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504423A5 (https=) | ||
| CA3083327A1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| JP2020508339A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2023002662A5 (https=) | ||
| JP2007514750A5 (https=) | ||
| JP2022009125A5 (https=) | ||
| JP2018131450A5 (https=) | ||
| AU2012229443B2 (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| JP2020508338A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| JP2010526101A5 (https=) | ||
| JP2014139255A5 (https=) | ||
| RU2627842C2 (ru) | Средство для улучшения диастолической функции левого желудочка | |
| JP2022529208A5 (https=) | ||
| JP2019218379A5 (https=) | ||
| TW201416095A (zh) | 包含格米列汀與美氟明的組合藥物及其製備方法 | |
| JP2020510043A5 (https=) | ||
| JP2008534473A5 (https=) | ||
| JOP20250127A1 (ar) | علاج مرض الكلى المزمن في مرض السكري من النوع الأول | |
| ES2366570T3 (es) | Asociación de un inhibidor de la corriente if sinusal y de un inhibidor de la enzima de conversión de la angiotensina. | |
| JPWO2023163203A5 (https=) | ||
| WO2006104086A1 (ja) | 血栓症治療剤 | |
| Canpolat et al. | Allergic reaction to proton pump ınhibitor: Pantoprazole ınduced Kounis syndrome | |
| JP5982715B2 (ja) | 抗高血圧薬組成物 |